1. Inhibit plasminogen activators, so that plasminogen cannot be activated into plasmin, thereby inhibiting the dissolution of fibrin and producing a hemostatic effect; 2. Promote the release of active substances by platelets, enhance platelet aggregation and adhesion, shorten coagulation time, and produce a hemostatic effect; 3. Enhance capillary resistance, reduce capillary permeability, and thus reduce bleeding.

Extract from the above information

This product has strong anti-inflammatory, liver cell membrane protection and liver function improvement effects. Pharmacological experiments have shown that oral administration of this product to mice can reduce the increase of serum alanine aminotransferase and aspartate aminotransferase caused by carbon tetrachloride, thioacetamide and D-galactosamine. It can also significantly reduce the morphological damage of D-galactosamine to the liver and improve the chronic damage of immune factors to the liver morphology.

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.